DS Investment & Securities analyzed on the 10th that Hanmi Pharmaceutical will enter a structural recovery phase this year. The target stock price was lowered from 440,000 won to 380,000 won ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback